RIMI - Repository of the Institute for Medical Research
Institute for Medical Research
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   RIMI
  • Institut za medicinska istraživanja
  • Radovi istraživača / Researchers' publications
  • View Item
  •   RIMI
  • Institut za medicinska istraživanja
  • Radovi istraživača / Researchers' publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Myeloid-Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets

Thumbnail
2019
959.pdf (24.43Mb)
Authors
Bizymi, Nikoleta
Bjelica, Sunčica
Kittang, Astrid Olsnes
Mojsilović, Slavko
Velegraki, Maria
Pontikoglou, Charalampos
Roussel, Mikael
Ersvaer, Elisabeth
Santibanez, Juan
Lipoldova, Marie
Papadaki, Helen A.
Article (Published version)
Metadata
Show full item record
Abstract
Myeloid-derived suppressor cells (MDSC) are a heterogeneous group of immature myeloid cells that exist at very low numbers in healthy subjects but can expand significantly in malignant, infectious, and chronic inflammatory diseases. These cells are characterized as early-MDSCs, monocytic-MDSCs, and polymorphonuclear-MDSCs and can be studied on the basis of their immunophenotypic characteristics and their functional properties to suppress T-cell activation and proliferation. MDSCs have emerged as important contributors to tumor expansion and chronic inflammation progression by inducing immunosuppressive mechanisms, angiogenesis and drug resistance. Most experimental and clinical studies concerning MDSCs have been mainly focused on solid tumors. In recent years, however, the implication of MDSCs in the immune dysregulation associated with hematologic malignancies, immune-mediated cytopenias and allogeneic hemopoietic stem cell transplantation has been documented and the potential role of... these cells as biomarkers and therapeutic targets has started to attract a particular interest in hematology. The elucidation of the molecular and signaling pathways associated with the generation, expansion and function of MDSCs in malignant and immune-mediated hematologic diseases and the clarification of mechanisms related to the circulation and the crosstalk of MDSCs with malignant cells and other components of the immune system are anticipated to lead to novel therapeutic strategies. This review summarizes all available evidence on the implication of MDSCs in hematologic diseases highlighting the challenges and perspectives arising from this novel field of research.

Source:
Hemasphere, 2019, 3, 1
Publisher:
  • Lippincott Williams & Wilkins, Philadelphia
Funding / projects:
  • COST action
  • COST action [BM1404 - Mye-EUNITER]
  • Alexander S. Onassis, Public Benefit Foundation in Greece Scholarship

DOI: 10.1097/HS9.0000000000000168

ISSN: 2572-9241

PubMed: 31723807

WoS: 000507915600007

Scopus: 2-s2.0-85087829414
[ Google Scholar ]
30
25
URI
http://rimi.imi.bg.ac.rs/handle/123456789/962
Collections
  • Radovi istraživača / Researchers' publications
Institution/Community
Institut za medicinska istraživanja
TY  - JOUR
AU  - Bizymi, Nikoleta
AU  - Bjelica, Sunčica
AU  - Kittang, Astrid Olsnes
AU  - Mojsilović, Slavko
AU  - Velegraki, Maria
AU  - Pontikoglou, Charalampos
AU  - Roussel, Mikael
AU  - Ersvaer, Elisabeth
AU  - Santibanez, Juan
AU  - Lipoldova, Marie
AU  - Papadaki, Helen A.
PY  - 2019
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/962
AB  - Myeloid-derived suppressor cells (MDSC) are a heterogeneous group of immature myeloid cells that exist at very low numbers in healthy subjects but can expand significantly in malignant, infectious, and chronic inflammatory diseases. These cells are characterized as early-MDSCs, monocytic-MDSCs, and polymorphonuclear-MDSCs and can be studied on the basis of their immunophenotypic characteristics and their functional properties to suppress T-cell activation and proliferation. MDSCs have emerged as important contributors to tumor expansion and chronic inflammation progression by inducing immunosuppressive mechanisms, angiogenesis and drug resistance. Most experimental and clinical studies concerning MDSCs have been mainly focused on solid tumors. In recent years, however, the implication of MDSCs in the immune dysregulation associated with hematologic malignancies, immune-mediated cytopenias and allogeneic hemopoietic stem cell transplantation has been documented and the potential role of these cells as biomarkers and therapeutic targets has started to attract a particular interest in hematology. The elucidation of the molecular and signaling pathways associated with the generation, expansion and function of MDSCs in malignant and immune-mediated hematologic diseases and the clarification of mechanisms related to the circulation and the crosstalk of MDSCs with malignant cells and other components of the immune system are anticipated to lead to novel therapeutic strategies. This review summarizes all available evidence on the implication of MDSCs in hematologic diseases highlighting the challenges and perspectives arising from this novel field of research.
PB  - Lippincott Williams & Wilkins, Philadelphia
T2  - Hemasphere
T1  - Myeloid-Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets
IS  - 1
VL  - 3
DO  - 10.1097/HS9.0000000000000168
ER  - 
@article{
author = "Bizymi, Nikoleta and Bjelica, Sunčica and Kittang, Astrid Olsnes and Mojsilović, Slavko and Velegraki, Maria and Pontikoglou, Charalampos and Roussel, Mikael and Ersvaer, Elisabeth and Santibanez, Juan and Lipoldova, Marie and Papadaki, Helen A.",
year = "2019",
abstract = "Myeloid-derived suppressor cells (MDSC) are a heterogeneous group of immature myeloid cells that exist at very low numbers in healthy subjects but can expand significantly in malignant, infectious, and chronic inflammatory diseases. These cells are characterized as early-MDSCs, monocytic-MDSCs, and polymorphonuclear-MDSCs and can be studied on the basis of their immunophenotypic characteristics and their functional properties to suppress T-cell activation and proliferation. MDSCs have emerged as important contributors to tumor expansion and chronic inflammation progression by inducing immunosuppressive mechanisms, angiogenesis and drug resistance. Most experimental and clinical studies concerning MDSCs have been mainly focused on solid tumors. In recent years, however, the implication of MDSCs in the immune dysregulation associated with hematologic malignancies, immune-mediated cytopenias and allogeneic hemopoietic stem cell transplantation has been documented and the potential role of these cells as biomarkers and therapeutic targets has started to attract a particular interest in hematology. The elucidation of the molecular and signaling pathways associated with the generation, expansion and function of MDSCs in malignant and immune-mediated hematologic diseases and the clarification of mechanisms related to the circulation and the crosstalk of MDSCs with malignant cells and other components of the immune system are anticipated to lead to novel therapeutic strategies. This review summarizes all available evidence on the implication of MDSCs in hematologic diseases highlighting the challenges and perspectives arising from this novel field of research.",
publisher = "Lippincott Williams & Wilkins, Philadelphia",
journal = "Hemasphere",
title = "Myeloid-Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets",
number = "1",
volume = "3",
doi = "10.1097/HS9.0000000000000168"
}
Bizymi, N., Bjelica, S., Kittang, A. O., Mojsilović, S., Velegraki, M., Pontikoglou, C., Roussel, M., Ersvaer, E., Santibanez, J., Lipoldova, M.,& Papadaki, H. A.. (2019). Myeloid-Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets. in Hemasphere
Lippincott Williams & Wilkins, Philadelphia., 3(1).
https://doi.org/10.1097/HS9.0000000000000168
conv_4563
Bizymi N, Bjelica S, Kittang AO, Mojsilović S, Velegraki M, Pontikoglou C, Roussel M, Ersvaer E, Santibanez J, Lipoldova M, Papadaki HA. Myeloid-Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets. in Hemasphere. 2019;3(1).
doi:10.1097/HS9.0000000000000168
conv_4563 .
Bizymi, Nikoleta, Bjelica, Sunčica, Kittang, Astrid Olsnes, Mojsilović, Slavko, Velegraki, Maria, Pontikoglou, Charalampos, Roussel, Mikael, Ersvaer, Elisabeth, Santibanez, Juan, Lipoldova, Marie, Papadaki, Helen A., "Myeloid-Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets" in Hemasphere, 3, no. 1 (2019),
https://doi.org/10.1097/HS9.0000000000000168 .,
conv_4563 .

DSpace software copyright © 2002-2015  DuraSpace
About RIMI | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About RIMI | Send Feedback

OpenAIRERCUB